![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
PF-05221304 (PF'1304), a liver-targeted acetyl-CoA carboxylase inhibitor (ACCi), in adults with nonalcoholic fatty liver disease (NAFLD) demonstrates robust reductions in liver fat and ALT-Phase 2a, dose-ranging study
|
|
|
AASLD Boston, Massachusetts November 8-11 2019
Neeta B. Amin*, Santos Carvajal-Gonzalez*, Naresh Aggarwal, Theresa A. Tuthill*, Malgorzata Inglot, Arthur Bergman*, William Esler*
*Pfizer Inc. employees
![1205191](../images/120619/120619-3/1205191.gif)
![1205192](../images/120619/120619-3/1205192.gif)
![1205193](../images/120619/120619-3/1205193.gif)
![1205194](../images/120619/120619-3/1205194.gif)
![1205195](../images/120619/120619-3/1205195.gif)
![1205196](../images/120619/120619-3/1205196.gif)
![1205197](../images/120619/120619-3/1205197.gif)
![1205198](../images/120619/120619-3/1205198.gif)
![1205199](../images/120619/120619-3/1205199.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|